-
Voices from China at the EBMT Annual Meeting Prof. Lu Peihua: CD7 CAR-T Breaks Through in Rare High-Risk Leukemia and Reshapes the Treatment Landscape of MPAL
As hematologic malignancy treatment advances toward precision medicine and cellular therapy, relapsed/refractory mixed phenotype acute leukemia (MPAL) remains a major clinical challenge due to its rarity and aggressive nature.
-
Voices from China at the EBMT Annual Meeting Recipient-Derived (Donor-Chimeric) CAR-T with Multimodal Strategies for Early Relapse After Allo-HSCT
At the 52nd EBMT Annual Meeting held in Madrid in March 2026, the team led by Prof. Zhang Yajing presented a novel therapeutic approach targeting one of the most challenging clinical scenarios in hematology—early relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
-
EAU26 | Professor Yi-Jun Shen on the HERO Study: Disitamab Vedotin Plus BCG Shows Promise in HR-NMIBC
Non–muscle-invasive bladder cancer (NMIBC) carries a substantial risk of postoperative recurrence, particularly in high-risk and very high-risk patients, where the 5-year recurrence rate can exceed 50%. In recent years, beyond traditional Bacillus Calmette–Guérin (BCG) intravesical therapy, the emergence of immune checkpoint inhibitors (ICIs) and antibody–drug conjugates (ADCs) has provided new therapeutic options to reduce recurrence…
-
ASCO GU On-site Report | Dr. Aly-Khan A. Lalani Presents CYTOSHRINK Trial Results: Early Dual Immunotherapy Combined with SBRT Shows Promise for Durable Responses in Advanced Renal Cancer
The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded. Numerous landmark studies in genitourinary oncology were presented, providing key evidence to inform and refine clinical practice. Among them, the phase II randomized CYTOSHRINK trial, focusing on treatment-naïve advanced renal cell carcinoma, reported its latest findings, offering important insights…
-
Voices from China at the EBMT Annual Meeting /Prof. Huang He: Engineering the Next Frontier — Armored and In Vivo CAR-T Cells Driving a New Wave in Cellular Therapy
From March 22 to 25, 2026, the 52nd EBMT Annual Meeting was held in Madrid, Spain, bringing together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
-
Voices from China at the EBMT Annual Meeting Prof. Jianping Zhang: High CD34⁺ Cell Dose Significantly Reduces EBV Reactivation and Improves Survival in Pediatric Aplastic Anemia Patients Undergoing UCBT
Pediatric aplastic anemia (AA) patients undergoing umbilical cord blood transplantation (UCBT) face outcomes that are closely tied to the infused cell dose. While recommended CD34⁺ cell doses have been established for hematologic malignancies, no clear standard exists for AA, leaving an important gap in clinical decision-making.
-
Voices from China at the EBMT Annual Meeting Prof. Peihua Lu / Prof. Yanli Zhao: Long-Term Outcomes of HSCT in Elderly Patients with Hematologic Malignancies—A Single-Center Comparison of Haploidentical, Matched Sibling, and Matched Unrelated Donors
Allogeneic hematopoietic stem cell transplantation (HSCT) in elderly patients with hematologic malignancies remains associated with substantial treatment-related risks. Choosing among haploidentical, matched sibling, and matched unrelated donors remains challenging due to the lack of robust head-to-head comparative data.
-
Voices from China at the EBMT Annual Meeting Prof. Hui Wang / Prof. Man Chen: CD72 as a Meaningful Marker and Target for MRD Assessment After CD19 CAR-T Therapy in B-ALL
Although CD19 CAR-T therapy achieves high remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), relapse driven by CD19 antigen loss poses a major challenge for MRD monitoring and long-term disease management. Identifying more stable biomarkers has therefore become essential for improving response assessment and prognostic evaluation.
Connecting Medical Expertise through Media